On this SynBioBeta podcast, John Cumbers talks with Sean McClain, founder, and CEO of Absci, a generative AI drug creation company on a mission to create better drugs for patients faster. Sean and John will continue some of the discussion that we started on the SynBioBeta stage around generative AI and its critical role in drug discovery, some news from AbSci’s recent R&D day, and Sean’s recent visit to Congress to discuss the opportunities and threats from AI and bio.

Sean McClain is the Founder and CEO of Absci, which he built from a basement lab to a publicly traded company that continues to strive towards his vision of creating therapeutics at the click of a button. Under his leadership, Absci scaled to over 200 employees, raised over $450M in capital, established a growing number of industry-leading partnerships and built an Integrated Drug Creation Platform that merges bleeding-edge generative AI models with proprietary high-throughput wet-lab data. Sean studied biochemistry and molecular biology at the University of Arizona and has been the recipient of numerous recognitions for his entrepreneurship and innovation. He serves as a board member for the Oregon Translational Research and Development Institute and Life Science Washington.

‍

Connect with Sean: @SeanRMcClain

Connect with John: @johncumbers